Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07186192

Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy

The overall purpose of this randomized control trial (RCT) is to determine the clinical effect of a multilevel, RPM-enhanced intervention during and after completion of outpatient CAR-T therapy in 190 patients and their family caregivers (FCGs).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

City of Hope Medical Center

Duarte, California, 91010, United States

Location status: Recruiting

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient Inclusion Criteria Informed Consent and Willingness to Participate

  • Documented informed consent of the participant and/or legally authorized representative Age and Language Criteria
  • Age ≥ 18 years old at the time of enrollment
  • Ability to read and understand English or Spanish for Questionnaires Nature of Illness and Treatment Related Criteria
  • Relapsed or refractory hematologic malignancy
  • Scheduled to receive outpatient standard of care (SOC) CAR-T therapy
  • Has a FCG committed to living with the patient for the duration of the study

Family Caregiver Inclusion Criteria Informed Consent and Willingness to Participate

  • Documented informed consent of the participant and/or legally authorized representative Age and Language Criteria
  • Age ≥ 18 years old at the time of enrollment
  • Ability to read and understand English or Spanish for Questionnaires Nature of Illness and Treatment Related Criteria
  • Family member or friend identified by the patient and defined as a person who knows the patient well and is involved in the patient's medical care

Exclusion criteria

1. An employee who is under the direct/indirect supervision of the PI/ a co-investigator/ the study manager 2. A direct study team member

-

Treatment and study plan

Educational Intervention

Other

Patients and family caregivers that are randomized into the intervetnion arm (Digital health intervention) will receive a 90 day nurse-drive, digital health intervention. Participate in self-management coaching sessions

Other names: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

Health Telemonitoring

Procedure

Wear a FitBit device and use a mobile app for nurse tracking

Questionnaire Administration

Other

Ancillary studies

Best Practice

Other

Given usual care

Other names: best practice, standard of care, standard of care, standard of care, standard therapy

Primary outcomes

  1. MD Anderson Symptom Inventory CAR-T module (MDASI-CAR - patient)

    Time frame: Baseline, Day 15 - Day 20 post-CAR-T, Day 30, Day 60, and Day 90

    This is validated measure of 22 CAR-T specific symptoms and other cancer-related symptoms. Symptom severity is rated on a 10-point scale: 1-3 mild, 4-6 moderate, ≥7 severe. Patients also rate how much their symptoms interfere with 6 functional domains: walking, activity, working/housework, relationships, enjoyment of life, and mood. A change in 1.2 points is clinically meaningful and cutoffs for clinical deficits have been defined. Cronbach's α reliability: 82-0.94.

  2. Distress Thermometer (DT - FCG)

    Time frame: Baseline, Day 15 - Day 20 post-CAR-T, Day 30, Day 60, and Day 90

    This is an efficient, low-subject-burden measure to evaluate psychological distress over the past week, based on a scale of 0 (no distress) to 10 (extremely distressed). A cut-off of 3/10 indicates a need for intervention, with acceptable sensitivity (94.1%) and specificity (71.2%) compared to the longer Hospital Anxiety and Depression Scale (HADS). The DT has been validated in FCGs, and we chose it for its brevity, accuracy ease of use in remote monitoring, and validity in FCGs.

Secondary outcomes

  1. Montgomery Borgatta Caregiver Burden Scale (FCG)

    Time frame: Baseline, Day 30, Day 60, and Day 90

    This is a 14-item tool designed to measure the impact of caregiving on three dimensions of burden: objective, subjective demand, and subjective stress. Internal consistency for the three dimensions ranges from 0.81-0.90. The ordinal scale ranges from 1-5 (a lot less to a lot more). The following cutoff scores are interpreted as high burden: 1) a score of ≥23 for objective burden, 2) a score of ≥15 for subjective demand, and 3) a score of ≥13.5 for subjective stress.

  2. Functional Assessment of Cancer Therapy-General (FACTG - patient)

    Time frame: Baseline, Day 30, Day 60, and Day 90

    This is a cancer-specific version of the FACIT (Functional Assessment of Chronic Illness Therapy) Measurement System. It contains a 27-item compilation of general questions divided into four QoL domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being. For each item, the respondent indicates on a 5-point Likert scale (0=not at all; 4=very much) how true each statement is for him/her during the past 7d. The FACT-G yields a total score for overall QoL as well as subscale scores. Internal consistency and reliability measures revealed a Cronbach's α of 0.89 for the total FACT-G, and a range of 0.70-0.82 for the four subscales.

Other outcomes

  1. COH-QoL-Family (FCG)

    Time frame: Baseline, Day 30, Day 60, and Day 90

    This is a 37-item instrument that measures FCG QoL in the physical, psychological, social, and spiritual well-being domains. Ordinal scale ranges from 0-10, with higher scores indicating better QoL. The instrument was revised and tested from 1994-1998 in a study of 219 FCGs of cancer patients. The test-retest reliability was r=0.89 and internal consistency was α r=0.69.

  2. Brief Dyadic Adjustment Scale (DAS - patient, FCG)

    Time frame: Baseline, Day 30, Day 60, and Day 90

    This is a 4-item scale designed to assess marital satisfaction for couples married or in a committed relationship. This instrument measures patient/FCG consensus, satisfaction, affectional expression and cohesion that directly assess general communication between couples. Alpha coefficients have been reported from 0.92 to 0.95. The measure will be included as a covariate for analysis. will be used to assess marital satisfaction (Patient, FCG).

  3. FCG Activation in Transitions Tool (FCAT - FCG)

    Time frame: Baseline, Day 30, Day 60, and Day 90

    This is a 10-item survey designed to assess FCG's level of engagement and preparedness to care for patients during care transitions. Psychometric assessment was conducted in two randomly equivalent waves of participants (N=434), including FCGs of patients with cancer and/or chronic lung disease. The estimated person-separation reliability was 0.84.

  4. Patient Activation Measure (PAM - patient)

    Time frame: Baseline, Day 30, Day 60, and Day 90

    This is a measure of patient "activation", which uses a Guttman-like scale that reflects patient level of engagement and empowerment in their healthcare. Cronbach's α from our pilot study was 0.92.

  5. PROMIS Self-Efficacy for Managing Symptoms Short Forms 8a (patient)

    Time frame: Baseline, Day 30, Day 60, and Day 90

    This is a brief, 8-item questionnaire used to assess an individual's confidence in their ability to manage specific aspects of symptoms. Specifically, the tool measures confidence in managing symptoms during daily activities, social interactions, and in public places.

  6. Self-Efficacy Scale (FCG)

    Time frame: Baseline, Day 30, Day 60, and Day 90

    This is a modified version of the Self-Efficacy Scale. Contains 8 items that assess FCG perceived confidence in self-management. Uses a 4-point Likert scale; higher scores represent greater confidence. Cronbach's α from our pilot: 0.89.

  7. Sociodemographic and Health Status (patient)

    Time frame: Baseline

    This is a questionnaire to assess patient demographics.

  8. FCG Demographics (FCG)

    Time frame: Baseline

    This is a questionnaire to assess patient demographics.

  9. Acceptability of Intervention (AIM) - Acceptability

    Time frame: Patients: Day 90 only; CAR-T clinical care team: before intervention starts and after intervention ends

    This is a questionnaire used to assess patient, family caregiver, and CAR-T clinical care team on acceptability of the intervention.

  10. Intervention Appropriateness Measure (IAM) - Appropriateness

    Time frame: Patients: Day 90 only; CAR-T clinical care team: before intervention starts and after intervention ends

    This is a questionnaire used to assess patient, family caregiver, and CAR-T clinical care team on the appropriateness of the intervention.

  11. Feasibility of Intervention (FIM)

    Time frame: Patients: Day 90 only; CAR-T clinical care team: before intervention starts and after intervention ends

    This is a questionnaire used to assess patient, family caregiver, and CAR-T clinical care team on the feasibility of the intervention.

Study contacts

Contact information is provided by the study sponsor or research team.

Virginia Sun, PhD, RN

CONTACT

[email protected]

626-218-3122

Sponsors and collaborators

Lead sponsor

City of Hope Medical Center

Other

Collaborators

  • United States Department of Defense

Registry information

Official study title

Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor-T Cell (CAR-T)Therapy

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Sep 22, 2025
Registry last updated
Jan 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.